Show simple item record

dc.contributor.authorNathwani, Rahul
dc.date.accessioned2021-08-04T07:10:37Z
dc.date.available2021-08-04T07:10:37Z
dc.date.issued2020
dc.identifier.other204-2020.94
dc.identifier.urihttps://repository.mbru.ac.ae/handle/1/405
dc.description.abstractAbstract: Ulcerative colitis and Crohn’s disease are the main entities of inflammatory bowel disease characterized by chronic remittent inflammation of the gastrointestinal tract. The incidence and prevalence are on the rise worldwide, and the heterogeneity between patients and within individuals over time is striking. The progressive advance in our understanding of the etiopathogenesis coupled with an unprecedented increase in therapeutic options have changed the management towards evidence-based interventions by clinicians with patients. This guideline was stimulated and supported by the Emirates Gastroenterology and Hepatology Society following a systematic review and a Delphi consensus process that provided evidence- and expert opinion-based recommendations. Comprehensive up-to-date guidance is provided regarding diagnosis, evaluation of disease severity, appropriate and timely use of different investigations, choice of appropriate therapy for induction and remission phase according to disease severity, and management of main complications.  en_US
dc.subjectUlcerative colitisen_US
dc.subjectCrohn’s diseaseen_US
dc.subjectInfliximaben_US
dc.subjectAdalimumaben_US
dc.subjectVedolizumaben_US
dc.subjectUstekinumaben_US
dc.subjectTofacitiniben_US
dc.titleFirst United Arab Emirates consensus on diagnosis and management of inflammatory bowel diseases: A 2020 Delphi consensusen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record